Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Clinical trial NCT05176483 · RECRUITING

Trial details

NCT number: NCT05176483
Sponsor: Exelixis
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Renal Cell Carcinoma (RCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Urothelial Carcinoma (UC)Solid Tumor Hepatocellular Carcinoma (HCC)Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Head and Neck Squamous Cell Carcinoma (HNSCC)Clear Cell Renal Cell Carcinoma (ccRCC)Non-Clear Cell Renal Cell Carcinoma (nccRCC)Drug-Drug Interaction (DDI)

Start date: 2021-12-14
Primary completion: 2027-01-31
Enrollment: 1394

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.